Ekf Diagnostics Dividends - EKF

Ekf Diagnostics Dividends - EKF

Buy
Sell
Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Ekf Diagnostics Holdings Plc EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change Price Change % Stock Price Last Trade
0.50 0.68% 74.00 16:29:29
Open Price Low Price High Price Close Price Previous Close
75.50 73.00 76.00 74.00 73.50
more quote information »
Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Ekf Diagnostics EKF Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
14/09/2020InterimGBX130/12/201930/06/202004/11/202005/11/202001/12/20200

Top Dividend Posts

DateSubject
13/1/2021
14:35
srichardson8: part of the staement from my broker and possibly on the EKF website 'EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited, at which time an `omnibus` share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled. During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares.'
09/1/2021
18:19
pldazzle: I have emailed the company as follows: Dear Sirs I hold x,xxx Ordinary shares in EKF Diagnostics PLC. I have received a letter from yourselves - signed in facsimile by Salim Hamir, Company Secretary - stating that I now hold x,xxx "Dividend Trellus Shares". This is the same number as my holding of EKF shares. I am aware that at least one other shareholder has received a similar letter. Contrariwise, EKF's successive RNS announcements have stated that the dividend in specie was to be in the ratio 1 Trellus : 16.25 EKF. By my reckoning, accordingly, I should now be the holder of yyy Trellus shares rather than x,xxx. Can you please confirm (a) that the letter I received is authentic and genuine, and (b) that it is incorrect and that a replacement letter will be sent out. On a separate matter, can you please let me know when and in what form the value of the dividend in specie will be announced. This is for the purposes of my 2020/21 tax return, which I wish to submit promptly this year. Yours faithfully
09/1/2021
15:32
pldazzle: I have received a letter from EKF dated 8 January - have others received one too? - purporting to confirm that I am the holder of [x] number of "A ordinary shares of nominal value £0.0001 each in Trellus Health Limited (the 'Dividend Trellus shares'". [x] is the identical number of shares as my holding in EKF, i.e. according to this letter I now hold 1 Trellus share for each 1 EKF share. EKF's RNS of 14 December stated: "The Company's shareholders on the register as at close of business on 17 December 2020 ("Relevant EKF Shareholders") will receive one A Share (each a "Dividend Share") for every 16.25 ordinary share [sic] held in the Company." Which is it then: 1 for 1, or 1 for 16.25? Has the company or its registrar slipped up?
08/1/2021
07:12
wan: 7th January 2021 EKF fly the extra mile over Christmas EKF fly the extra mile over Christmas PrimeStore - EKF fly the extra mile over Christmas 3 Like Santa, the EKF Diagnostics logistics team took to the skies over the Christmas holidays. Faced with the problem of sending 160,000 tubes of PrimeStore MTM to a customer in Ireland with a tight deadline and the uncertainty around border control due to the Brexit negotiations, the team at EKF’s Barleben facility charted an aircraft and flew 18 pallets directly to Dublin Airport. Thanks to the efficiency of our team and their colleagues at DB Schenker the consignment reached Dublin within three hours, ready to be collected by our distributor, Syntec. hTTps://www.ekfdiagnostics.com/ekf-fly-the-extra-mile-over-christmas.html
17/12/2020
13:14
wan: As indicated by the CEO, Trellus will not be the last value creation to come out of the EKF/Mount Sinai partnership. And although EKF will also be a cash dividend payer, the spinout opportunities (and ultimately the best use of EKF 'growing' cash pile) will return greater value to investors. Even like those of us who follow EKF closely, we only have the track record to go by, and in this regard Renalytix delivered circa 23p to patient EKF investors and then went onto deliver a lot more, including Verici (and I suspect there is more to come from both of these). I firmly believe Trellus will follow a similar path in terms of delivery to EKF investors. And I am sure most investors are fully behind the management with regard to this value creation policy. What we don't know is what's coming next in terms of potential spinouts, but only the patient investors will find out and ultimately realize the benefit. In the meantime, the core business continues to advance and grow, as do their relationships, which are now extending further.
14/12/2020
07:31
masurenguy: 14 December 2020: Approval of dividend in specie of investment in Trellus Health "Approval by shareholders was granted at the General Meeting held on 10 December 2020, to distribute the Company's entire holding of A Ordinary Shares in Trellus ("A Shares") by way of a dividend in specie to EKF Shareholders on the register at 17 December 2020. The Company's shareholders on the register as at close of business on 17 December 2020 ("Relevant EKF Shareholders") will receive one A Share (each a "Dividend Share") for every 16.25 ordinary share held in the Company. Relevant EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited ("Broadway"), at which time an 'omnibus' share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of: -- 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or -- if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled (the "Lock-up Period"). During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares. Relevant EKF Shareholders will receive a letter informing them of their beneficial holdings of Dividend Shares shortly after the transfer of the Dividend Shares to Broadway. Following the Lock-up Period, Relevant EKF Shareholders will receive individual certificates in respect of their Dividend Shares.
08/12/2020
07:34
wan: One assumes that the commencement of mass-manufacturing in the US has now resulted in availability and roll-out here too - EKF introduces accurate quantitative COVID-19 antibody test kit Cardiff, UK – 7 December 2020 – EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals. Unlike other antibody tests, the Kantaro COVID-SeroKlir SARS-CoV-2 IgG antibody test kit determines both the presence and specific quantities of human IgG antibodies to the SARS-CoV-2 virus. This enables a broad range of COVID-19 applications, such as delivering vital knowledge for advancing the understanding of protective immunity, assessing vaccine response and accelerating therapeutic treatments. The high performance quantitative COVID-SeroKlir kit has received FDA Emergency Use Authorization (EUA) and is CE marked. It has demonstrated 98.8% sensitivity and 99.6% specificity for detecting SARS-CoV-2 specific IgG antibodies against two SARS-CoV-2 virus antigens, the full-length spike protein and its receptor-binding domain (RBD). This confirmed accuracy means false positives and false negatives are minimized. The best-in-class serologic COVID-19 assay is based on technology developed by clinicians at the Icahn School of Medicine at Mount Sinai Health System in New York in partnership with RenalytixAI, a spinout company from EKF Diagnostics. Here, COVID-SeroKlir has been validated on a highly diverse cohort of more than 75,000 patients, including over 30,000 who were diagnosed with COVID-19; this is more than any other COVID-19 test. In addition, the test has been independently verified by peer reviewed journals, including Nature and Science [1, 2], as well as the U.S. National Institutes of Health (NIH). The Mount Sinai study also demonstrated that over 90% of infected individuals with mild-to-moderate COVID-19 experience robust IgG antibody responses against the viral spike protein [2]. In addition, these COVID-19 neutralizing antibody levels were confirmed to be relatively stable during the first five months after infection. Explaining the value of knowing the precise levels of SARS-CoV-2 IgG antibodies, Julian Baines, CEO of EKF, said, “Quantitative IgG antibody testing can provide important support for determining public health strategies, informing healthcare decision making, and verifying the effectiveness of vaccines as they become available. It is also an essential component of a general health check to determine past COVID-19 infections. This is because COVID-19 has been linked with an increased risk of potentially life-threatening complications, including lung, kidney, and cardiovascular disease.” EKF holds exclusive rights to market and distribute the Kantaro COVID-SeroKlir kit in the UK and Germany, and non-exclusive rights in the rest of Europe. Julian Baines added, “With the capacity to manufacture up to 10 million tests per month, EKF is well placed to drive rapid availability of COVID-SeroKlir kits to a broad range of laboratories for immediate operation without needing specialized testing equipment.” Full release - hTTps://www.ekfdiagnostics.com/ekf-introduces-accurate-quantitative-covid-19-antibody-test-kit.html
27/11/2020
13:14
wan: Here is another thought for the day. EKF have already confirmed they intend to maintain a dividend policy. So, if we assume that the dividend will be the same, or greater than the current 1p dividend per share, what value might we also factor in for the potential in-specie dividend for Trellus Health? With the main thrust being, what the prospective dividend yield might be in relation to the current share price. Even if you want to be conservative and assume the total dividend (including Trellus Health) as amounting to only 2p, that gives a prospective yield of over 3% (based on the current mid price). Of course this does not then account for the growth on offer from a successful IPO of Trellus, and subsequently the direct exposure to the digital health opportunity, which is experiencing rapid rates of growth, increased investor interest, and attracting increasing amounts of corporate activity.
17/11/2020
14:28
wan: If you agree on the testing front, then that sits somewhat awkwardly with your view on the effect from vaccines. Has the market discounted in the potential from the low-cost ATM product? In this regard the jury is definitely out, in other words, it appears to have discounted in not much coming from ATM. So time will tell. (but Longhorns comments/confidence are firmly in my mind). Has the market discounted in the 'potential' IPO of Trellus Health (note EKF's track record)? I think not, but time will tell. Has the market discounted in the rebound in the core business? To a degree maybe. Has the market discounted in the growth from the imminent new life science products? I don't think so. EKF's growing cash and marketable investments might mean next years dividend will be increased. Likewise, investors will be supportive if they use some of that cash to support further partnerships with Mount Sinai, with a view to going down the IPO route and distribute further dividends in-specie. How would the market discount that unknown but real potential? What could Trellus Health be worth? What could the resulting dividend in-specie be worth, what would the cash dividend and the potential Trellus Health in-specie dividend combined be worth in terms of dividend yield? Has the market correctly discounted the potential from the new antibody tests, especially in relation to the vaccine news? Difficult to say, but it should be noted that understanding the level of immune response, or how the vaccine response may behave differently to the response from natural infection, and understanding the duration of protection will remain uncertain for a number of years (amongst others aspects), but will be of key interest. So an accurate, data rich, diverse clinical use quantitative antibody test should be in demand, and that demand and interest should last for a number of years, not months. Because up until now, the vaccines manufacturers don't know the answers yet, and nor does the market! In short, I am not sure EKF get the in-depth coverage for 'everything' to be discounted. But I could be wrong, so please conduct your own research.
27/10/2020
07:43
mginvestor: From the SourceBio Admission Document the related party transactions part mentions EKF: Distribution Agreement between Source BioScience UK Limited and EKF Diagnostics Holdings plc Christopher Mills, a non-executive director of SourceBio is a director of EKF Diagnostics Holdings plc (EKF). On 1 May 2020, Source BioScience UK Limited (“SBUL”) entered into a distribution agreement with EKF under which EKF manufactures PrimeStore MTM tubes (the “Products̶1;), used for the provision of COVID-19 testing services, and supplies them to SBUL. Title to the Products does not pass to SBUL until EKF has received payment in full in cleared funds. Once settled, SBUL may then sell the Products in certain exclusive territories, namely England, Wales, Scotland, Jersey, Guernsey and any such other countries as mutually agreed between the parties. The agreement commenced on 28 April 2020 for a duration of one year, after which it will automatically renew on an annual basis for a period of one year at a time. The agreement shall come to an end if a termination event occurs, in accordance with the agreement, or if one party gives the other 60 days’ written notice of its intention to terminate the agreement. The agreement grants SBUL the right to use a number of EKF’s trademarks and also contains various undertakings, warranties and indemnities given by each party to the other. SBUL is prohibited from selling or manufacturing products which directly or indirectly compete with EKF, save with EKF’s consent. The agreement refers to volumes being agreed between the parties in writing from time to time. The Company has confirmed no minimum volume commitments are currently in place.
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210119 06:23:44